Implementing the concept of environmental protection and fulfilling the corporate social responsibility, committed to becoming the world’s leading sustainable pharmaceutical enterprise
Undertaking corporate social responsibility ("CSR") to build healthy, harmonious and sustainable communities
On 7 January 2025, a magnitude 6.8 earthquake, which struck at a depth of 10 km, hit Tingri County, Shigatse City in Tibet, causing heavy casualties and house damages. Caring about the disaster, China Medical System Holdings Limited (“CMS”) has made proactive disaster relief efforts through its wholly-owned subsidiary, Tibet Kangzhe Pharmaceutical Development Co., Ltd. On January 9th, it donated relief supplies worth nearly RMB 0.5 million to the earthquake-stricken area through Tibet Development Philanthropic Foundation, including disinfectant, military coats, cotton quilts, and cotton jackets, etc. Moreover, on January 13th, it donated a special fund of RMB2 million to Tibet Charity Federation for post-disaster resettlement and reconstruction, to further help the disaster area to overcome the difficulties sooner. Join hands to fight the disaster, and pray for peace and safety. CMS wishes the earthquake-stricken area in Shigatse, Tibet rebuild their homes as earlier as possible.
Recently, Healthcare Executive (“E药经理人”), in collaboration with a leading independent corporate social responsibility consulting agency in China, released the results of 2024 “Chinese Pharmaceutical Listed Companies ESG Competitiveness” series ranking. The ranking aims to recognize Chinese pharmaceutical companies that serve as benchmarks in various aspects of ESG management. By virtue of its continuous efforts in sustainable development and low-carbon initiatives, China Medical System (“CMS” or the “Group”) has been selected into the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Mid-cap Stocks)” ranking for three consecutive years, and has also been included in the inaugural “Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies” ranking. As an active practitioner of the sustainable development concept, CMS steadily responds to the United Nations Sustainable Development Goals, and promotes the deep integration of ESG governance with its macro strategies and business operations. With adherence to high standards of business ethics in its operations, the Group has established a scientific and effective risk identification […]
In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its “AA” rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating Report. Re-including in S&P Global’s Sustainability Yearbook (China Edition) The S&P Global’s 2024 Sustainability Yearbook (China Edition) has been released. With an CSA score of 51 that surpassing 91% global peers in the industry, CMS stood out among more than 1,700 evaluated Chinese companies to be reincluded in the China Yearbook, becoming one of the five selected companies in the pharmaceutical industry. Source: S&P Global Receiving “AA” once again in MSCI ESG Rating In July, MSCI has released the latest ESG rating report for CMS. The Group […]